Skip to Content
Merck
  • Determination of early cardiac deterioration in beta-thalassaemia major by echocardiography.

Determination of early cardiac deterioration in beta-thalassaemia major by echocardiography.

Acta cardiologica (2013-07-26)
Oner Ozdogan, Alper Alp, Meral Turker, Berna Atabey
ABSTRACT

Cardiovascular involvement is the leading cause of mortality in patients with beta-thalassaemia major (beta-TM). This cross-sectional study was performed to evaluate the earlier cardiac damage in beta-TM by echocardiography, before left ventricular (LV) systolic dysfunction was observed. The study population consisted of 70 patients with beta-TM and was compared with age- and sex-matched healthy controls (n= 47). The study population was divided into subgroups based on serum ferritin levels and the time interval from first diagnosis. All patients and control subjects underwent transthoracic echocardiography. Mean LV ejection fractions were similar between groups (60 +/- 5% vs 62+/- 6%, P= 0.063). beta-TM patients had increased left atrial (LA) volume index, LV mass index, and right ventricle (RV) diameter index (30.3 +/- 9.9 vs 19.9 +/- 4.8, 97.0 +/-17.8 vs 80.2 +/- 13.6, and 1.50 +/- 0.17 vs 1.31 +/- 0.15; P= 0.0001, respectively). Patients with beta-TM had significantly shortened pulmonary acceleration times (133.7+/- 22.4 vs 154.9 +/- 16.5, P= 0.0001). Mitral early inflow (E) velocity and tissue Doppler (TDI) annular velocity (Em) ratios (E/Em) were also elevated (7.5 +/- 3.0 vs 6.2 +/- 1.6, respectively, P= 0.009). Serum levels of ferritin were correlated with interventricular septum (R= 0.308, P= 0.009) and posterior wall (R= 0.312, P= 0.009) thicknesses. It is often unsuccessful to reverse iron-induced cardiac deterioration in late-stage disease when cardiac failure is already present. Increased LV mass index, LA volume index, RV diameter index, and decreased pulmonary acceleration time could be earlier parameters featuring premature cardiac remodelling in beta-TM. Increased E/Em ratio may also point out early cardiac deterioration in beta-TM patients.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Ferritin from human spleen, Type V, 10 μg/mL in 0.15 M NaCl, 10 mM Tris, pH 8.0, containing 0.1% sodium azide
Sigma-Aldrich
Ferritin from equine spleen, Type I, saline solution
Sigma-Aldrich
Ferritin from human liver, Type IV, 10 μg/mL